BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 30, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 4/27 cls
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Brean Murray Jonathan Aschoff Price target Buy -1% $90.56
Jefferies Eun Yang Price target Hold
ThinkEquity Marko Kozul Price target Buy
Aschoff raised his target to $105 from $85 after Alexion reported 1Q12 EPS and revenues that beat the consensus estimates (see EPS Watch, A16). The biotech raised 2012 revenue guidance to $1.07-$1.08B from $1.04-$1.07B and non-GAAP EPS guidance to $1.65-$1.75 from $1.60-$1.70 Aschoff expects Alexion to be at the upper end of the new revenue guidance range and "would not be at all surprised" if it beat. Alexion markets Soliris eculizumab to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); both the rare blood disorders.
Yang raised her target to $76 from $68 on earnings.
Kozul raised...

Read the full 995 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >